Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Business Strategies Sales & Earnings

Biogen says it will up Samsung Bioepis cut

  • News

Executive Summary

Biogen has confirmed plans to purchase a 49.9% equity stake in the Samsung Bioepis biosimilars joint venture between itself and Samsung BioLogics, praising the “attractive, value-creation opportunity”.

You may also be interested in...



Biogen Exits Joint Venture As Samsung Biologics Buys Out Bioepis

Biogen’s stake in Samsung Bioepis has been fully acquired by former partner Samsung Biologics, following an announcement of the deal in January.

Biogen Sells Samsung Bioepis Stake In $2.3bn Buyout

Biogen has struck a deal that will see it sell its equity stake in the Samsung Bioepis biosimilars joint venture to partner Samsung Biologics for up to $2.3bn.

Teva Shows Its Big Pharma Clout With $1.5bn Sanofi Deal

Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.

Table

View full table

Topics

Tags:
Business Strategies Sales & Earnings
Latest Headlines

‘Parts Of The Dream Are Coming True’ – Narayan Marks Progress On Value Added Medicines In Europe

Stada Grows China Presence Through CR Sanjiu Partnership

Teva Shows Its Big Pharma Clout With $1.5bn Sanofi Deal

Apotex And Ambio Shatter Hopes Of Teriparatide Exclusivity For Teva

See All
UsernamePublicRestriction

Register

GB000681

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By